Trial Profile
A Phase II Clinical Trial of Pembrolizumab as Monotherapy and in Combination With Cisplatin+5-Fluorouracil in Subjects With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Mar 2024
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Capecitabine; Cisplatin; Fluorouracil
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms KEYNOTE-059
- Sponsors Merck Sharp & Dohme; Merck Sharp & Dohme Corp.
- 11 Sep 2023 Result of pooled analysis from KEYNOTE-001,KEYNOTE-059, KEYNOTE-048, KEYNOTE-427, KEYNOTE-052, KEYNOTE-361 assessing Tumor dynamics in patients with solid tumors treated with pembrolizumab beyond disease progression published in the Cancer Cell
- 01 Oct 2022 Results (n=1194) of retrospective analysis of two studies(KEYNOTE-001 and KEYNOTE-059) assessing Lesion-to-lesion heterogeneity in response to pembrolizumab therapy presented at the CRI-ENCI-AACR 6th Annual International Cancer, Immunotherapy Conference
- 21 Sep 2021 Results assessing genomic landscape of late-stage gastric cancer from these two studies (KEYNOTE-059 and KEYNOTE-061) presented at the 46th European Society for Medical Oncology Congress